STOCK TITAN

Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Avid Bioservices, Inc. (NASDAQ:CDMO) to Report Q2 Fiscal Year 2024 Financial Results on December 7, 2023
Positive
  • None.
Negative
  • None.

TUSTIN, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2024 on December 7, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the second quarter and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.

About Avid Bioservices, Inc.

Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 30 years of experience producing biologics, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com


FAQ

When will Avid Bioservices, Inc. report financial results for Q2 fiscal year 2024?

Avid Bioservices, Inc. will report financial results for the second quarter of fiscal year 2024 on December 7, 2023, after market close.

What is the ticker symbol for Avid Bioservices, Inc.?

The ticker symbol for Avid Bioservices, Inc. is NASDAQ:CDMO.

Where can I access the webcast for Avid Bioservices, Inc.'s financial results?

To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.

Avid Bioservices, Inc.

NASDAQ:CDMO

CDMO Rankings

CDMO Latest News

CDMO Stock Data

516.73M
58.33M
1.1%
91.92%
15.99%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
TUSTIN

About CDMO

avid bioservices, a subsidiary of peregrine pharmaceuticals, inc. (nasdaq: pphm), is a unique contract manufacturing organization ("cmo") partner dedicated to the development and production of monoclonal antibodies, recombinant proteins and enzymes produced in mammalian cell culture. our extensive experience at all stages of development enables us to provide comprehensive development, manufacturing and support services to navigate a biologic from concept to commercialization.